Charles Schwab’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History

Charles Schwab’s Portfolio SIOX Stock Details SIOX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-20,023	Closed	-$26K	–	3643
2021 Q4	$26K	Hold	20,023	–	–	﹤0.01%	3569
2021 Q3	$44K	Hold	20,023	–	–	﹤0.01%	3467
2021 Q2	$55K	Buy	+20,023	New	+$49.8K	﹤0.01%	3357
2018 Q2	–	Sell	-7,263	Closed	-$78K	–	3163
2018 Q1	$78K	Hold	7,263	–	–	﹤0.01%	3055
2017 Q4	$307K	Hold	7,263	–	–	﹤0.01%	2870
2017 Q3	$400K	Buy	7,263 +1,038	+17%	+$175K	﹤0.01%	2780
2017 Q2	$1.16M	Buy	6,225 +1,525	+32%	+$267K	﹤0.01%	2407
2017 Q1	$562K	Hold	4,700	–	–	﹤0.01%	2605
2016 Q4	$467K	Hold	4,700	–	–	﹤0.01%	2678
2016 Q3	$527K	Hold	4,700	–	–	﹤0.01%	2599
2016 Q2	$483K	Buy	4,700 +2,250	+92%	+$225K	﹤0.01%	2600
2016 Q1	$226K	Hold	2,450	–	–	﹤0.01%	2861
2015 Q4	$354K	Buy	+2,450	New	+$319K	﹤0.01%	2798

Other funds holding SIOX

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

CIA

Cladis Investment Advisory Billings, Montana $182M AUM 33.3% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return

Charles Schwab's SIOX Position: Q1 2022 in Review

Charles Schwab sold out of Sio Gene Therapies Inc. Common Stock (SIOX) in Q1 2022, closing a stake of 20,023 shares — an estimated $26K sold.

Charles Schwab first reported a position in SIOX in Q4 2015 and held it in 13 quarters. The position peaked at $1.16M in Q2 2017. 41 funds tracked by Wall St. Rank hold SIOX as of Q1 2022.

Charles Schwab reported no remaining Sio Gene Therapies Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
Charles Schwab sold 20,023 Sio Gene Therapies Inc. Common Stock shares in Q1 2022, an estimated $26K.
Charles Schwab first reported a position in Sio Gene Therapies Inc. Common Stock in Q4 2015 and held it in 13 quarters.
Charles Schwab's Sio Gene Therapies Inc. Common Stock position peaked at $1.16M in Q2 2017.
41 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q1 2022.

Based on Charles Schwab's 13F filing for Q1 2022, filed 13 May 2022.